116 related articles for article (PubMed ID: 12820810)
1. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.
Robbins BL; Wilcox CK; Fridland A; Rodman JH
Pharmacotherapy; 2003 Jun; 23(6):695-701. PubMed ID: 12820810
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
3. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases.
Birkus G; Kutty N; He GX; Mulato A; Lee W; McDermott M; Cihlar T
Mol Pharmacol; 2008 Jul; 74(1):92-100. PubMed ID: 18430788
[TBL] [Abstract][Full Text] [Related]
4. Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.
Kewn S; Hoggard PG; Henry-Mowatt JS; Veal GJ; Sales SD; Barry MG; Back DJ
AIDS Res Hum Retroviruses; 1999 Jun; 15(9):793-802. PubMed ID: 10381167
[TBL] [Abstract][Full Text] [Related]
5. Cellular phosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key intermediate in the activation of the antiviral agent DDI, in human peripheral blood mononuclear cells.
Robbins BL; Greenhaw J; Fridland A
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):405-13. PubMed ID: 10772723
[TBL] [Abstract][Full Text] [Related]
6. Analysis and validation of the phosphorylated metabolites of two anti-human immunodeficiency virus nucleotides (stavudine and didanosine) by pressure-assisted CE-ESI-MS/MS in cell extracts: sensitivity enhancement by the use of perfluorinated acids and alcohols as coaxial sheath-liquid make-up constituents.
Bezy V; Chaimbault P; Morin P; Unger SE; Bernard MC; Agrofoglio LA
Electrophoresis; 2006 Jun; 27(12):2464-76. PubMed ID: 16786481
[TBL] [Abstract][Full Text] [Related]
7. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Guo Y; Fung HB
Pharmacotherapy; 2004 Aug; 24(8):1089-94. PubMed ID: 15338857
[TBL] [Abstract][Full Text] [Related]
8. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
[TBL] [Abstract][Full Text] [Related]
9. Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.
Ray AS; Vela JE; Boojamra CG; Zhang L; Hui H; Callebaut C; Stray K; Lin KY; Gao Y; Mackman RL; Cihlar T
Antimicrob Agents Chemother; 2008 Feb; 52(2):648-54. PubMed ID: 18056281
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Antoniou T; Park-Wyllie LY; Tseng AL
Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
[TBL] [Abstract][Full Text] [Related]
12. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Hoggard PG; Manion V; Barry MG; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):164-7. PubMed ID: 9491831
[TBL] [Abstract][Full Text] [Related]
13. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.
Ray AS; Olson L; Fridland A
Antimicrob Agents Chemother; 2004 Apr; 48(4):1089-95. PubMed ID: 15047506
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
15. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.
Robbins BL; Srinivas RV; Kim C; Bischofberger N; Fridland A
Antimicrob Agents Chemother; 1998 Mar; 42(3):612-7. PubMed ID: 9517941
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate.
Grim SA; Romanelli F
Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir poses risk with didanosine.
AIDS Patient Care STDS; 2003 Jun; 17(6):309. PubMed ID: 12880494
[No Abstract] [Full Text] [Related]
18. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
[TBL] [Abstract][Full Text] [Related]
19. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Negredo E; Moltó J; Burger D; Viciana P; Ribera E; Paredes R; Juan M; Ruiz L; Puig J; Pruvost A; Grassi J; Masmitjà E; Clotet B
AIDS; 2004 Feb; 18(3):459-63. PubMed ID: 15090798
[TBL] [Abstract][Full Text] [Related]
20. Effect of tenofovir on didanosine absorption in patients with HIV.
Pecora Fulco P; Kirian MA
Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
